随着年龄的增长,大脑和外围组织中阿德罗宾水平的变化
Changjun Yang1, John Aaron Howell1, Lei Liu1
1Department of Neuroscience, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Neuroscience letters
|February 8, 2025
概括
衰老显著降低了大脑的阿德罗宾和NB-3水平,可能导致认知能力下降. 这项研究强调了特定于大脑的衰退,表明神经系统疾病的治疗点.
科学领域:
- 神经科学是一个神经科学.
- 衰老研究研究 衰老研究
- 分子生物学分子生物学
背景情况:
- 阿德罗是一种涉及神经健康的生物活性.
- 衰老与大脑阿德罗宾的降低以及潜在的神经系统疾病,如中风和认知能力下降有关.
- 衰老对外周腺素的影响及其与神经分子NB-3/接触素-6的关系是未知的.
研究的目的:
- 研究衰老对大脑和外围组织中阿德罗宾水平的影响.
- 为了检查衰老,阿德罗和神经识别分子NB-3/接触素-6之间的关系.
- 探索阿德罗降低,NB-3水平和衰老大脑中的氧化应激标志物之间的相关性.
主要方法:
- 在年轻和老年雄性小鼠的大脑和外围组织中使用免疫阻塞对阿德罗宾的量化.
- 在小鼠大脑中测量NB-3/接触素-6水平.
- 同免疫沉以评估阿德罗和NB-3之间的关联.
- 对氧化应激标志物的分析 (gp91phox,4-hydroxynonenal).
主要成果:
- 与年轻对照小鼠相比,在老年小鼠中观察到大脑阿德罗宾水平的显著下降.
- 周围组织的阿德罗水平没有显示出与年龄相关的显著变化.
- 老年大脑表现出较低的NB-3/接触素-6水平,这在物理上与阿德罗宾有关.
- 大脑中与年龄相关的阿德罗宾减少与增加的氧化应激标志物相关.
结论:
- 老龄化导致大脑阿德罗宾和NB-3水平的同时下降,与外围组织不同.
- 这种与年龄相关的大脑特异性的阿德罗和NB-3的减少可能会导致神经功能障碍.
- 维持大脑氨酸水平是缓解大脑衰老和相关疾病的潜在治疗策略.
相关概念视频
Aging
35
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
35
Alzheimer's Disease: Overview
432
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
432
Cognitive Development During Adulthood
46
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
46
Drugs Affecting Neurotransmitter Synthesis
1.2K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.2K
Role of Neurotransmitters in Memory
396
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
396
Factors Affecting Protein-Drug Binding: Patient-Related Factors
34
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
34


